These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 25816025

  • 21. Identification of a uromodulin fragment for diagnosis of IgA nephropathy.
    Wu J, Wang N, Wang J, Xie Y, Li Y, Liang T, Wang J, Yin Z, He K, Chen X.
    Rapid Commun Mass Spectrom; 2010 Jul 30; 24(14):1971-8. PubMed ID: 20552702
    [Abstract] [Full Text] [Related]

  • 22. Noninvasive Urinary Monitoring of Progression in IgA Nephropathy.
    Yang JYC, Sarwal RD, Fervenza FC, Sarwal MM, Lafayette RA.
    Int J Mol Sci; 2019 Sep 10; 20(18):. PubMed ID: 31510053
    [Abstract] [Full Text] [Related]

  • 23. The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy.
    Torres DD, Rossini M, Manno C, Mattace-Raso F, D'Altri C, Ranieri E, Pontrelli P, Grandaliano G, Gesualdo L, Schena FP.
    Kidney Int; 2008 Feb 10; 73(3):327-33. PubMed ID: 17943082
    [Abstract] [Full Text] [Related]

  • 24. Clinicopathological features and outcomes of IgA nephropathy with hematuria and/or minimal proteinuria.
    Tan M, Li W, Zou G, Zhang C, Fang J.
    Kidney Blood Press Res; 2015 Feb 10; 40(2):200-6. PubMed ID: 25924707
    [Abstract] [Full Text] [Related]

  • 25. [Variable number of tandem repeats polymorphism of MUC20 is associated with the progression of IgA nephropathy].
    Li GS, Zhang H, Lü JC, Hou P, Zhou Y, Ma XZ, Wang HY.
    Zhonghua Yi Xue Za Zhi; 2005 May 25; 85(19):1333-8. PubMed ID: 16029633
    [Abstract] [Full Text] [Related]

  • 26. Factors predicting progression of IgA nephropathies.
    Coppo R, D'Amico G.
    J Nephrol; 2005 May 25; 18(5):503-12. PubMed ID: 16299675
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of renal clinicopathological changes in IgA nephropathy by urinary podocytes excretion and podocalyxin expression.
    Jiang WL, Peng YM, Liu YH, Liu H, Chen GC, Xu XQ, Zhu XJ, Liu FY.
    Ren Fail; 2012 May 25; 34(7):821-6. PubMed ID: 22679920
    [Abstract] [Full Text] [Related]

  • 28. Discovery of Fibrinogen γ-chain as a potential urinary biomarker for renal interstitial fibrosis in IgA nephropathy.
    Guan J, Wang M, Zhao M, Ni W, Zhang M.
    BMC Nephrol; 2023 Mar 20; 24(1):60. PubMed ID: 36941570
    [Abstract] [Full Text] [Related]

  • 29. Urinary exosomal miRNA-451a can be used as a potential noninvasive biomarker for diagnosis, reflecting tubulointerstitial damage and therapeutic response in IgA nephropathy.
    Zhang Q, Zhao Y, Luo Y, Guo S, Hou H, Han X, Zhou Y.
    Ren Fail; 2024 Dec 20; 46(1):2319326. PubMed ID: 38379319
    [Abstract] [Full Text] [Related]

  • 30. Renal expression of trefoil factor 3 mRNA in association with tubulointerstitial fibrosis in IgA nephropathy.
    Tanaka K, Sugiyama H, Yamanari T, Mise K, Morinaga H, Kitagawa M, Onishi A, Ogawa-Akiyama A, Tanabe K, Eguchi J, Ohmoto Y, Shikata K, Wada J.
    Nephrology (Carlton); 2018 Sep 20; 23(9):855-862. PubMed ID: 29987860
    [Abstract] [Full Text] [Related]

  • 31. Selection of urinary sediment miRNAs as specific biomarkers of IgA nephropathy.
    Duan ZY, Cai GY, Bu R, Lu Y, Hou K, Chen XM.
    Sci Rep; 2016 Mar 22; 6():23498. PubMed ID: 27000966
    [Abstract] [Full Text] [Related]

  • 32. Validation of some pathophysiological mechanisms of the CKD progression theory and outcome prediction in IgA nephropathy.
    Bazzi C, Rizza V, Casellato D, Stivali G, Rachele G, Napodano P, Olivieri G, Gallieni M, D'Amico G.
    J Nephrol; 2012 Mar 22; 25(5):810-8. PubMed ID: 22252844
    [Abstract] [Full Text] [Related]

  • 33. Clinical course and prognostic factors of clinical early IgA nephropathy.
    Shen P, He L, Huang D.
    Neth J Med; 2008 Jun 22; 66(6):242-7. PubMed ID: 18689907
    [Abstract] [Full Text] [Related]

  • 34. The role of urine IgG in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis.
    Xu X, Huang X, Chen Y, Li J, Shen M, Hou Y, Lin X, Lin Q, Liu X, Bao K, Wang L, Yang H, Liu L, Zou C.
    Int Urol Nephrol; 2022 Feb 22; 54(2):323-330. PubMed ID: 33871780
    [Abstract] [Full Text] [Related]

  • 35. Clinical significance of urinary inflammatory biomarkers in patients with IgA nephropathy.
    Yoon SY, Kim JS, Jung SW, Kim YG, Moon JY, Lee SH, Yim SV, Hwang HS, Jeong K.
    BMC Nephrol; 2024 Apr 22; 25(1):142. PubMed ID: 38649936
    [Abstract] [Full Text] [Related]

  • 36. Urinary kidney injury molecule-1 is related to pathologic involvement in IgA nephropathy with normotension, normal renal function and mild proteinuria.
    Xu PC, Wei L, Shang WY, Tian SL, Gu DM, Yan TK, Lin S.
    BMC Nephrol; 2014 Jul 07; 15():107. PubMed ID: 24998891
    [Abstract] [Full Text] [Related]

  • 37. Urinary Periostin Excretion Predicts Renal Outcome in IgA Nephropathy.
    Hwang JH, Lee JP, Kim CT, Yang SH, Kim JH, An JN, Moon KC, Lee H, Oh YK, Joo KW, Kim DK, Kim YS, Lim CS.
    Am J Nephrol; 2016 Jul 07; 44(6):481-492. PubMed ID: 27802442
    [Abstract] [Full Text] [Related]

  • 38. Imbalance of regulatory T cells to Th17 cells in IgA nephropathy.
    Lin FJ, Jiang GR, Shan JP, Zhu C, Zou J, Wu XR.
    Scand J Clin Lab Invest; 2012 May 07; 72(3):221-9. PubMed ID: 22276947
    [Abstract] [Full Text] [Related]

  • 39. Urinary miRNA profile for the diagnosis of IgA nephropathy.
    Szeto CC, Wang G, Ng JK, Kwan BC, Mac-Moune Lai F, Chow KM, Luk CC, Lai KB, Li PK.
    BMC Nephrol; 2019 Mar 04; 20(1):77. PubMed ID: 30832601
    [Abstract] [Full Text] [Related]

  • 40. Effect of treatment on urinary kidney injury molecule-1 in IgA nephropathy.
    Seo MS, Park MY, Choi SJ, Jeon JS, Noh H, Kim JK, Han DC, Hwang SD, Jin SY, Kwon SH.
    BMC Nephrol; 2013 Jul 09; 14():139. PubMed ID: 23837450
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.